-
[show abstract]
[hide abstract]
ABSTRACT: Novel pentafluorophenyl (PFP)-ester-functionalized phosphorylcholine (PC) polymers of different architectures were prepared and conjugated to lysozyme as a model protein. Linear and two-arm poly(2-methacryloyloxyethyl phosphorylcholine) (polyMPC) structures containing PFP functionality at the chain-end were prepared by atom transfer radical polymerization (ATRP) from novel initiators. Additional conjugates were prepared from phosphorylcholine-substituted cyclooctene (PC-COE) polymers containing PFP-ester bearing comonomers. The polymer-protein conjugates were characterized by HPLC, FPLC, and DLS and were seen to retain most (~80% or greater) of their native enzymatic activity. Pharmacokinetic profiles of the polymer-protein conjugates were studied in mice and found to increase the circulation half-life compared with lysozyme alone.
Biomacromolecules 06/2012; 13(7):2099-109. · 5.48 Impact Factor
-
Advanced Functional Materials 08/2010; 20(20):3603 - 3612. · 10.18 Impact Factor
-
07/2010;
-
[show abstract]
[hide abstract]
ABSTRACT: Phosphorylcholine (PC)-substitution on aliphatic polyesters is accomplished by click chemistry with PC-substituted azides.
Chemical Communications 03/2009; · 6.17 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Polymer-protein conjugation was performed using N-hydroxysuccinimide and aldehyde-terminated zwitterionic polymers, and the resulting polymer-protein conjugates were characterized by gel electrophoresis and fast protein liquid chromatography. Methacryloyloxyethyl phosphorylcholine (MPC) polymers were prepared by atom transfer radical polymerization in which the requisite functional end-groups for protein conjugation were embedded within the polymerization initiators. These phosphorylcholine polymers were conjugated to lysozyme as a model protein, as well as two therapeutic proteins, granulocyte colony stimulating factor (G-CSF) and erythropoietin (EPO). These MPC polymer-protein conjugates represent alternatives to PEGylated proteins, with the potential to provide improved efficacy in a therapeutic treatment relative to the protein itself.
Biomacromolecules 10/2008; 9(10):2891-7. · 5.48 Impact Factor
-
01/2008;